Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

PROTECT Investigators, Martin Nitschke

Fingerprint

Dive into the research topics of 'Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial'. Together they form a unique fingerprint.

Medicine & Life Sciences